The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical rhinometry, to determine the prevalence of non-allergic rhinitis with local IgE elevation in this study's cohort of patients with non-allergic rhinitis identified by rhinitis history and negative skin testing for allergic rhinitis, and to determine the change, if any, in intranasal IgE levels after capsaicin treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline
Timeframe: baseline
Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Timeframe: 4 weeks post treatment
Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Timeframe: 12 weeks post treatment
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline
Timeframe: baseline
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Timeframe: 4 weeks post treatment
Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Timeframe: 12 weeks post treatment
Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline
Timeframe: baseline
Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Timeframe: 4 weeks post treatment
Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Timeframe: 12 weeks post treatment
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline
Timeframe: baseline
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Timeframe: 4 weeks post treatment
Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Timeframe: 12 weeks post treatment
Change in Maximum Optical Density Determined Via Optical Rhinometry
Timeframe: baseline, immediately post first treatment on Day 1
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at Baseline
Timeframe: baseline
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment
Timeframe: 4 weeks post treatment
Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment
Timeframe: 12 weeks post treatment
Maximum Optical Density Determined Via Optical Rhinometry
Timeframe: 12 weeks post treatment